BrainsWay (BWAY) Q1 2024: 37% Revenue Surge Signals Enterprise TMS Adoption Shift
BrainsWay delivered a 37% revenue jump, driven by accelerating institutional adoption and international expansion, while sustaining profitability momentum and cash generation. Strategic focus on enterprise mental health groups and new geographies is reshaping the installed base and pipeline quality. With robust backlog and disciplined reinvestment, management is positioning for sustained growth and further market share gains in both core and adjacent indications.
Summary
- Institutional Expansion Drives Growth: Enterprise and large mental health group partnerships are now the primary growth engine.
- Profitability Momentum Sustained: Operating leverage and cost discipline underpin positive cash flow and margin gains.
- Pipeline and Indication Diversification: Strategic bets on new protocols, indications, and geographies set up multi-year runway.
Business Overview
BrainsWay develops and commercializes Deep Transcranial Magnetic Stimulation (Deep TMS) systems, a noninvasive neurostimulation technology used for treating mental health disorders including depression and OCD. The company generates revenue through the sale and placement of Deep TMS systems, recurring consumables, and service agreements. Major segments include U.S. enterprise and private psychiatric practices, international markets, and new clinical indications.
Performance Analysis
BrainsWay delivered a standout first quarter, with revenue growing 37% year over year, marking a sharp acceleration versus prior periods and reflecting a step-change in demand from institutional and enterprise customers. Gross margin expanded by nearly 200 basis points, reaching 75%, as operating expenses fell 21% year over year, highlighting management’s focus on operating leverage and cost control. The company posted positive net income and adjusted EBITDA for the third consecutive quarter, with cash and equivalents rising to $47.8 million and no debt, underscoring a robust balance sheet and self-funding growth model.
System placements and recurring OCD indication add-ons both contributed materially, with 57 net systems shipped and 31 OCD coils added, bringing total installed base to 1,158 units. The U.S. pipeline remains strong, but international markets—especially Israel, Korea, Taiwan, and India—are emerging as meaningful contributors, aided by improved reimbursement and targeted commercial investments. BrainsWay’s ability to sustain both growth and profitability is increasingly underpinned by a mix shift toward larger, repeat customers and higher-value enterprise agreements.
- Enterprise Customer Acceleration: Large mental health groups, exemplified by Katie’s Way Plus, are scaling deployments, now representing a significant share of new placements.
- International Traction: Installations in new geographies, notably Israel and Asia, are benefiting from local reimbursement improvements and expanded sales leadership.
- Operating Cost Compression: Sales, R&D, and G&A expenses all declined year over year, driving a swing to operating profit and positive cash flow.
BrainsWay’s execution reflects a deliberate pivot toward higher-quality, repeat business and a disciplined approach to reinvestment, setting the stage for sustained, profitable growth.
Executive Commentary
"We continue to optimize our existing commercial process, including enhancing our emphasis on larger institutional and enterprise customers that are playing an increasingly important role within the industry."
Adar Levy, Chief Executive Officer
"Our backlog is strong and our booking as of Q1 was right on target as we anticipated. So we believe that this target and this guidance that we gave around the 37 to 40 million is covered by a strong backlog and a strong pipeline that we have that will enable us to achieve this target."
Ido Marone, Chief Financial Officer
Strategic Positioning
1. Enterprise Mental Health Networks as Core Growth Channel
BrainsWay’s pivot toward enterprise and institutional customers is transforming its commercial model. Partnerships like Katie’s Way Plus, which expanded to 40 devices, exemplify the move away from fragmented, one-off placements to scalable, recurring deployments. This shift increases revenue visibility, enhances account stickiness, and supports operating leverage as more large networks integrate Deep TMS into their standard protocols.
2. International Expansion and Reimbursement Leverage
International markets are emerging as a key growth lever, with recent installations in Israel following reimbursement rate increases and strong momentum in Korea, Taiwan, and India. The appointment of a new VP of International Sales with deep medtech experience signals intent to accelerate geographic diversification, reducing reliance on the U.S. and tapping into underpenetrated regions with favorable regulatory and payer dynamics.
3. Indication and Protocol Innovation
BrainsWay is investing in clinical expansion, targeting new indications (such as Parkinson’s, late-life depression, and addiction) and next-generation protocols (like accelerated TMS and TMS360). Ongoing trials, including a new FDA-backed study on short-course TMS, are designed to shorten treatment duration and improve patient access, further differentiating the platform and expanding addressable market.
4. R&D and Capital Allocation Discipline
Despite profitability gains, management is reinvesting in R&D and commercial resources, but with an explicit commitment to maintaining positive cash flow and margin momentum. The company also flagged openness to inorganic growth—potentially through acquisitions or in-licensing in adjacent neuro and addiction markets—though with a disciplined, opportunistic lens.
Key Considerations
This quarter marks a turning point in BrainsWay’s scale and business quality, as management’s commercial focus and cost discipline begin to yield sustainable operating leverage and cash generation. The interplay between enterprise growth, international expansion, and clinical innovation is driving a higher-value, more defensible business model.
Key Considerations:
- Enterprise Penetration Momentum: Large account wins like Katie’s Way Plus validate a replicable playbook for scaling within mental health networks and veterans-focused providers.
- International Upside: Reimbursement tailwinds and expanded commercial leadership position BrainsWay to leverage underpenetrated global markets.
- Clinical Pipeline Optionality: Accelerated TMS protocols and new indication trials offer multi-year growth levers, with regulatory and payer feedback likely to shape adoption curves.
- Disciplined Capital Deployment: Management is balancing reinvestment with profitability, prioritizing organic growth but remaining open to selective M&A in adjacent verticals.
Risks
BrainsWay’s growth trajectory is exposed to several risks: regulatory or reimbursement shifts in key markets could slow adoption, while clinical trial setbacks or slower-than-expected uptake of new protocols may limit pipeline optionality. Competitive intensity in neurostimulation and TMS markets remains high, and execution risk is elevated as the company scales internationally and across new customer types. Currency fluctuations and macroeconomic headwinds could also impact international revenue realization.
Forward Outlook
For Q2 2024, BrainsWay guided to:
- Continued strong system placements, with a run rate of 50-60 units per quarter expected to persist
- Positive cash flow and profitability momentum throughout the year
For full-year 2024, management reiterated guidance:
- Revenue of $37 million to $40 million, representing 16% to 26% growth over 2023
Management highlighted several factors that support this outlook:
- Robust U.S. and international pipeline, with bookings on target and backlog coverage for full-year targets
- Ongoing reinvestment in sales, marketing, and R&D to sustain growth, with spend calibrated to profitability objectives
Takeaways
BrainsWay’s Q1 results confirm a strategic inflection, with enterprise adoption, international momentum, and profitability gains converging to create a more scalable, defensible business.
- Enterprise and international expansion are now the primary growth engines, with large mental health groups and new geographies driving both top-line and quality of revenue.
- Disciplined cost management enabled a swing to profitability and cash generation, providing a foundation for reinvestment in R&D and commercial scale.
- Future performance will hinge on successful clinical expansion, continued enterprise penetration, and maintaining balance between growth and profitability as the business scales.
Conclusion
BrainsWay’s Q1 marks a decisive shift toward higher-value growth, with institutional and international expansion underpinning both revenue quality and operating leverage. The company’s disciplined approach to reinvestment and pipeline diversification positions it well for continued market share gains and long-term value creation.
Industry Read-Through
BrainsWay’s results highlight a broader trend in neurostimulation and mental health technology: institutional buyers and large provider networks are becoming the dominant channel, favoring scalable, evidence-based solutions with proven payer support. Reimbursement improvements and global expansion are increasingly critical for medtech adoption, while the ability to layer on new indications and protocols provides defensible competitive advantage. For peers in neuromodulation and digital mental health, the BrainsWay playbook—enterprise focus, international leverage, disciplined capital allocation—offers a roadmap for scaling profitably in a rapidly evolving landscape. Investors should monitor the pace of clinical innovation and payer adoption as key determinants of sector leadership.